BR112021002267A8 - Inibidores de prmt5 - Google Patents

Inibidores de prmt5

Info

Publication number
BR112021002267A8
BR112021002267A8 BR112021002267A BR112021002267A BR112021002267A8 BR 112021002267 A8 BR112021002267 A8 BR 112021002267A8 BR 112021002267 A BR112021002267 A BR 112021002267A BR 112021002267 A BR112021002267 A BR 112021002267A BR 112021002267 A8 BR112021002267 A8 BR 112021002267A8
Authority
BR
Brazil
Prior art keywords
formula
compounds
prmt5 inhibitors
methods
phhf
Prior art date
Application number
BR112021002267A
Other languages
English (en)
Other versions
BR112021002267A2 (pt
Inventor
Machacek Michelle
Witter David
Gibeau Craig
Huang Chunhui
Kawamura Shuhei
L Sloman David
Siliphaivanh Phieng
Quiroz Ryan
Wan Murray
schneider Sebastian
S Yeung Charles
H Reutershan Michael
J Henderson Timothy
Paparin Jean-Laurent
Rahali Houcine
Sanyal Sulagna
M E Hughes Jonathan
A Candito David
Ye Yingchun
M Silverman Steven
S Fier Patrick
Original Assignee
Merck Sharp & Dohme
Merck Sharp & Dohme Llc
Msd Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Merck Sharp & Dohme Llc, Msd Int Gmbh filed Critical Merck Sharp & Dohme
Publication of BR112021002267A2 publication Critical patent/BR112021002267A2/pt
Publication of BR112021002267A8 publication Critical patent/BR112021002267A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A presente invenção fornece um composto da Fórmula (I) e os sais farmaceuticamente aceitáveis, ésteres, e pró-fármacos dos mesmos, que são inibidores de PRMT5. Também são fornecidos métodos para fazer compostos da Fórmula I, composições farmacêuticas que compreendem compostos da Fórmula I, e métodos para usar esses compostos para tratar câncer, célula falciforme, e mutações de persistência hereditária de hemoglobina fetal (PHHF).
BR112021002267A 2018-08-07 2019-08-05 Inibidores de prmt5 BR112021002267A8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862715446P 2018-08-07 2018-08-07
US62/715,446 2018-08-07
US201962792623P 2019-01-15 2019-01-15
US62/792,623 2019-01-15
US201962859490P 2019-06-10 2019-06-10
US62/859,490 2019-06-10
PCT/US2019/045050 WO2020033288A1 (en) 2018-08-07 2019-08-05 Prmt5 inhibitors

Publications (2)

Publication Number Publication Date
BR112021002267A2 BR112021002267A2 (pt) 2021-05-04
BR112021002267A8 true BR112021002267A8 (pt) 2023-02-07

Family

ID=69414248

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021002267A BR112021002267A8 (pt) 2018-08-07 2019-08-05 Inibidores de prmt5

Country Status (11)

Country Link
US (1) US20220363707A1 (pt)
EP (1) EP3833355A4 (pt)
JP (1) JP7446282B2 (pt)
KR (1) KR20210046009A (pt)
CN (1) CN112805006A (pt)
AU (1) AU2019317549A1 (pt)
BR (1) BR112021002267A8 (pt)
CA (1) CA3108388A1 (pt)
MA (1) MA53287A (pt)
MX (1) MX2021001486A (pt)
WO (1) WO2020033288A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210089656A (ko) 2018-10-05 2021-07-16 버텍스 파마슈티칼스 인코포레이티드 알파-1 항트립신 조절제
JP2022522534A (ja) * 2019-04-02 2022-04-19 アリゴス セラピューティクス インコーポレイテッド Ｐｒｍｔ５を標的にする化合物
US11884672B2 (en) 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
AU2020283505A1 (en) * 2019-05-30 2021-12-23 Angex Pharmaceutical, Inc. Heterocyclic compounds as PRMT5 inhibitors
JP2023504279A (ja) 2019-12-03 2023-02-02 ルピン・リミテッド Ｐｒｍｔ５阻害剤としての置換ヌクレオシドアナログ
WO2021202480A1 (en) * 2020-04-01 2021-10-07 Aligos Therapeutics, Inc. Compounds targeting prmt5
EP4126819A1 (en) * 2020-04-03 2023-02-08 Vertex Pharmaceuticals Incorporated 7- or 8-hydroxy-isoquinoline and 7- or 8-hydroxy-quinoline derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd)
WO2023001133A1 (zh) * 2021-07-20 2023-01-26 上海齐鲁制药研究中心有限公司 Prmt5抑制剂
WO2023017152A1 (en) 2021-08-13 2023-02-16 Albert-Ludwigs-Universität Freiburg Specific small molecule inhibitors that block kmt9 methyltransferase activity and function
CN116655638B (zh) * 2022-05-12 2024-01-26 上海齐鲁制药研究中心有限公司 氘代prmt5抑制剂
TW202406908A (zh) * 2022-08-09 2024-02-16 大陸商上海湃隆生物科技有限公司 新型prmt5抑制劑及其應用
WO2024101965A1 (ko) * 2022-11-10 2024-05-16 에스케이바이오팜 주식회사 Prmt5 저해제와 dna 손상 유도 물질의 약학적 조합물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ700583A (en) * 2009-04-22 2016-04-29 Acad Of Science Czech Republic Novel 7-deazapurine nucleosides for therapeutic uses
WO2012170347A1 (en) * 2011-06-09 2012-12-13 Isis Pharmaceuticals, Inc. Bicyclic nucleosides and oligomeric compounds prepared therefrom
US20170198006A1 (en) * 2014-06-25 2017-07-13 Epizyme, Inc. Prmt5 inhibitors and uses thereof
TW202321249A (zh) * 2015-08-26 2023-06-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６－６雙環芳香環取代之核苷類似物
CN105837573B (zh) * 2016-03-28 2018-07-27 江西青峰药业有限公司 一种9-[3a,6-二羟基六氢-1H-环戊二烯并[c]呋喃-4-基]鸟嘌呤的制备方法
EA201990851A1 (ru) 2017-02-24 2019-09-30 Янссен Фармацевтика Нв Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
CA3072439A1 (en) * 2017-08-09 2019-02-14 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)

Also Published As

Publication number Publication date
EP3833355A4 (en) 2022-05-11
CN112805006A (zh) 2021-05-14
MA53287A (fr) 2022-05-11
KR20210046009A (ko) 2021-04-27
JP2022501316A (ja) 2022-01-06
AU2019317549A1 (en) 2021-02-25
CA3108388A1 (en) 2020-02-13
US20220363707A1 (en) 2022-11-17
JP7446282B2 (ja) 2024-03-08
EP3833355A1 (en) 2021-06-16
BR112021002267A2 (pt) 2021-05-04
MX2021001486A (es) 2021-07-15
WO2020033288A1 (en) 2020-02-13

Similar Documents

Publication Publication Date Title
BR112021002267A8 (pt) Inibidores de prmt5
AR108301A1 (es) Inhibidores de mcl-1 y métodos de uso de los mismos
CU20210065A7 (es) Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibitoria en cdk2
BR112022012032A2 (pt) Inibidores de prmt5
CL2022000603A1 (es) Inhibidores prmt5 cooperativos de mta
CU20210009A7 (es) Compuestos derivados de tieno pirrolo-triazina acetamida sustituida como inhibidores de la actividad inflamatoria de la proteína receptora tipo nod 3 (nlrp3)
EA201891703A1 (ru) Соединения бензопиразола и их аналоги
CU20210080A7 (es) Triazinas sustituidas como inhibidores de proteína tirosina fosfatasa
BR112018007381A2 (pt) compostos úteis como imunomoduladores
BR112017007769A2 (pt) compostos e composições para modulação de atividades de cinase de egfr mutante
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
BR112015014590A2 (pt) composto; composição farmacêutica; estojo ou farmacêutico empacotado; método de inibição de prmt5; método de alteração da expressão de genes; método de alteração da transcrição; e método de tratamento ou prevenção de um distúrbio mediado por prmt5
EA201290324A1 (ru) Киназные ингибиторы
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
TR201802944T4 (tr) İlaç olarak azai̇ndazol veya di̇azai̇ndazol türünün türevleri̇
BR112017009651A2 (pt) composto, composição farmacêutica, e, método para tratamento de uma infecção por protozoário intracelular, uma infecção viral ou um câncer.
BR112014028042A2 (pt) inibidores de nampt
BR112017018305A2 (pt) desacetoxitubulisina h e análogos da mesma
BR112013017362A2 (pt) composto de fórmula (i), processo para preparar um composto de fórmula (i), composição farmacêutica e compostos, métodos e usos inovadores
BR112021011325A2 (pt) Derivados de rapamicina
UY38614A (es) Derivados de benzodiazepinas como inhibidores del rsv
CL2022001741A1 (es) Compuestos cíclicos y métodos de uso de estos
UY37569A (es) Inhibidores del inmunoproteasoma
BR112023015425A2 (pt) Derivados de uracila como inibidores de trpa1

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: MSD INTERNATIONAL GMBH (CH) ; MERCK SHARP AND DOHME LLC (US)